The MariTide and the Treasury Hurdle (AMGN)
Amgen Inc. (AMGN) faces an earnings showdown where speculative obesity hype meets a 4.95% risk-free rate and a negative 1.50% FCF equity risk premium.
AMGN
Amgen Inc. (AMGN) faces an earnings showdown where speculative obesity hype meets a 4.95% risk-free rate and a negative 1.50% FCF equity risk premium.